Background
==========

Prognosis or clinical outcome of esophageal squamous cell carcinoma (ESCC) has markedly improved over the last several decades, owing to advancements in medical treatment. However, in Japan, 11,867 people succumbed to this disease in 2010, and esophageal cancer was the seventh most common cause of cancer mortality in men (3.4% of the total cancer deaths in Japan) \[[@B1]\]. Various prognostic markers have recently been evaluated, including the stem cell marker CD133 (Prominin-1), which was reported to be a cancer stem cell marker for cancers of the brain \[[@B2]\], colon \[[@B3],[@B4]\], prostate \[[@B5]\], liver \[[@B6],[@B7]\], lung \[[@B8]\], kidney \[[@B9]\], ovaries \[[@B10]\], and skin \[[@B11],[@B12]\]. It was also reported to be a marker of poor prognosis for cancers of the brain and spinal cord \[[@B13]\], colon \[[@B14]\], rectum \[[@B15]\], pancreas \[[@B16]\], breast \[[@B17]\], and stomach \[[@B18]\]. In addition, a potent cytotoxic drug, monomethyl auristatin F, which acts as an anti-CD133 antibody-drug conjugate for hepatocellular and gastric cancer cells, may be utilized to treat CD133-positive tumors \[[@B19]\]. To date, there have been limited studies of CD133 in esophageal cancer, and thus, the significance of CD133 in this form of cancer remains unclear. Therefore, we examined whether CD133 could serve as a prognostic marker of ESCC. In addition, we explored the correlation between CD133 expression and the clinicopathological findings of ESCC patients and the correlation between CD133 expression and the immunolocalization of several markers, such as p53, p16, p27, murine double minute 2 (MDM2), Ki-67, and epidermal growth factor receptor (EGFR), which are known as prognostic markers or tumor proliferation factors in ESCC \[[@B20]-[@B27]\].

Methods
=======

Patients and tissue samples
---------------------------

A total of 86 consecutive ESCC patients, who underwent curative surgery without neoadjuvant treatment at Tohoku University Hospital (Sendai, Japan) between January 2000 and December 2005, were selected. All patients underwent thoracoscopic esophagectomy with two- or three-field node dissection, except for four patients who underwent pharyngo-laryngo-esophagectomy with one-field node dissection, six patients who underwent transhiatal esophagectomy with one-field node dissection, and eight patients who underwent esophagectomy by right thoracotomy.

The resected specimens and lymph nodes were fixed in 10% formalin, and representative sections were embedded in paraffin wax. The sections were histologically examined according to the Union for International Cancer Control (UICC) TNM (tumor, node, metastasis) classification (7th edition) system \[[@B28]\]. Patient survival time was determined from the date of surgery until death, recurrence, or the last follow-up examination. This study was approved by the ethical committee of the Tohoku University Hospital (Accession number 2011--596).

Immunohistochemical staining and evaluation
-------------------------------------------

Serial sections (4 μm thick), including the deepest area of the tumors, were deparaffinized in xylene, rehydrated in graded alcohol, and immersed in 3.0% hydrogen peroxide in methanol for 10 min at room temperature (RT) to inhibit endogenous peroxidase activity. For antigen retrieval, the slides for p53 were heated by microwave irradiation at 95°C for 15 min in 0.01 M citrate buffer (pH 6.0). The slides for p16, p27, MDM2, and Ki-67 were heated by autoclave at 121°C for 5 min in 0.01 M citrate buffer (pH 6.0). The slides for CD133 were autoclaved at 121°C for 5 min in Histofine antigen retrieval solution (pH 9.0, Nichirei Biosciences Inc., Tokyo, Japan). The slides for EGFR were incubated in 0.05% protease in Tris--HCl buffer (pH 7.6) at 37°C for 10 min. After washing three times for 5 min each in phosphate-buffered saline (PBS), the slides were incubated in 1% normal rabbit serum for 30 min at RT to reduce nonspecific antibody binding and were subsequently incubated at 4°C overnight with mouse monoclonal antibody against p53 (DO-7, Leica Microsystems, Bannockburn, IL, USA, diluted 1/100), p16 (G175-1239, BD Biosciences, Franklin Lakes. NJ, USA, diluted 1/100), p27 (SX53G8, Dako, Glostrup, Denmark, diluted 1/800), MDM2 (SMP14, Santa Cruz Biotechnology Inc., CA, USA, diluted 1/1000), Ki-67 (MIB-1, Dako, diluted 1/300), EGFR (31G7, Nichirei Biosciences Inc., dilution unknown, product code 413701), CD133 (AC133, Miltenyi Biotec, Auburn, CA, USA, diluted 1/10). The following day, the sections were washed three times for 5 min each in PBS, incubated with biotinylated anti-mouse immunoglobulin (Nichirei Biosciences Inc.), washed three times for 5 min each in PBS, and incubated with peroxidase-labeled streptavidin (Nichirei Biosciences Inc.) for 30 min at RT. The immunohistochemical signal was visualized with 3,3^′^-diaminobenzidine, and the slides were counterstained with Mayer's hematoxylin, dehydrated in graded alcohol, and cleared in xylene. For CD133, omission of the primary antibody and substitution by nonspecific immunoglobulin (Mouse IgG1, Dako) at the same concentration were used as negative and isotype controls, respectively.

The sections were examined by two independent observers (HO and FF) who were blinded to patients' clinical information. The proportion of positive nuclei in more than 1,000 tumor cells of more than three fields under a ×400 magnification microscope (Leica DM LB2) at the deepest area of each tumor was calculated for p53, p27, MDM2, and Ki-67. The proportion of nuclei and cytoplasm of tumor cells positive for p16 was evaluated. The proportion of membranes of tumor cells positive for EGFR was evaluated. The cut-off values for abnormal expression were as follows: p53, ≥10% \[[@B21]\]; p16, ≤5% \[[@B26]\]; p27, ≥10% \[[@B25]\]; MDM2, ≥20% \[[@B29]\]; and Ki-67, ≥30% \[[@B27]\]. An immunoreactive score (IRS) was used for the scoring of EGFR. The IRS is obtained by multiplying the intensity score (0, no staining; 1, faint staining; 2, moderate staining; 3, strong staining) by the extent score (0, none; 1, \<10%; 2, 10 to 50%; 3, \>50 to 80%; 4, \>80%) and ranges from 1 to 12. An IRS of ≥6 was defined as positive for EGFR expression \[[@B20]\]. When evaluating CD133, the tumors were defined as positive and negative when \>1% and ≤1% of the membranes and cytoplasm of all tumor cells were immunostained, respectively \[[@B13],[@B30]\].

Statistical analyses
--------------------

Statistical analyses were performed using JMP Pro Version 9.0.2 (SAS Institute Inc., Cary, NC, USA). The correlation of factors was evaluated by the chi-square test, Fisher's exact test, or Wilcoxon test, as appropriate. Survival curves were determined by the Kaplan-Meier method, and differences in survival between groups were compared by the log-rank test. The Cox proportional hazard model was used for multivariate analysis. A *P* value of \<0.05 was considered statistically significant.

Results
=======

Correlation between CD133 and clinicopathological findings of patients
----------------------------------------------------------------------

Table  [1](#T1){ref-type="table"} summarizes the clinicopathological findings of the patients examined. The median follow-up time was 69.0 months (range, 1 to 149 months). The patients included 73 men and 13 women with a median age of 64 years (range, 37 to 81 years). The number of patients in each pathological stage was as follows: 20, pStageI; 28, pStageII; 33, pStageIII; and 5, pStageIV. There were five patients with M1 lymph nodes. Of the 86 patients, 38 (44.2%) were immunohistochemically positive for CD133 (Figure  [1](#F1){ref-type="fig"}). pT and pStage were significantly more advanced among CD133-negative patients compared with CD133-positive patients (Table  [1](#T1){ref-type="table"}).

![**Immunohistochemical staining of esophageal squamous cell carcinoma.** Tumor cells positive for CD133 **(A,B)**, p16 **(C)**, and p27 **(D)** expression (×400 magnification). In addition, **B**, **C**, and **D** were at the same site of the same tumor.](1477-7819-11-51-1){#F1}

###### 

Correlation between clinicopathological findings and CD133 status

                                       **Total (%)**   **CD133 expression**                ***P***
  ------------------------ ----------- --------------- ---------------------- ------------ ---------
  **Age (years)**          Mean ± SD   63.9 ± 9.4      64.8 ± 10.9            63.2 ± 8.0   0.45
                           (Range)     (37--81)        (37--9)                (44--81)     
  **Sex**                  Male        73 (84.9)       32 (84.2)              41 (85.4)    0.88
  Female                   13 (15.1)   6 (15.8)        7 (14.9)                            
  **Smoking**              Absent      13 (15.1)       8 (21.1)               5 (10.4)     0.17
  Present                  73 (84.9)   30 (79.0)       43 (89.6)                           
  **Location**             Cervix      5 (5.8)         3 (7.9)                2 (4.2)      0.59
  Upper                    5 (5.8)     1 (2.6)         4 (8.3)                             
  Middle                   35 (40.7)   17 (44.7)       18 (37.5)                           
  Lower                    41 (47.7)   17 (44.7)       24 (50.0)                           
  **Histological type**    Well        17 (19.8)       9 (23.7)               8 (16.7)     0.68
  Moderate                 56 (65.1)   23 (60.5)       33 (68.8)                           
  Poor                     13 (15.1)   6 (15.8)        7 (14.6)                            
  **pT**                   pT1         28 (32.6)       19 (50.0)              9 (18.8)     0.017
  pT2                      9 (10.5)    3 (7.9)         6 (12.5)                            
  pT3                      46 (53.5)   15 (39.5)       31 (64.6)                           
  pT4                      3 (3.5)     1 (2.6)         2 (4.2)                             
  **pN**                   pN0         36 (41.9)       19 (50.0)              17 (35.4)    0.17
  pN1-3                    50 (58.1)   19 (50.0)       31 (64.6)                           
  **pM**                   pM0         81 (94.2)       35 (92.1)              46 (95.8)    0.65
  pM1 (LYM)                5 (5.8)     3 (7.9)         2 (4.2)                             
  **pStage**               pStageI     20 (23.3)       14 (36.8)              6 (12.5)     0.035
  pStageII                 28 (32.6)   9 (23.7)        19 (39.6)                           
  pStageIII                33 (38.4)   12 (31.6)       21 (43.8)                           
  pStageIV                 5 (5.8)     3 (7.9)         2 (4.2)                             
  **Lymphatic invasion**   Negative    34 (39.5)       13 (34.2)              21 (43.8)    0.37
  Positive                 52 (60.5)   25 (65.8)       27 (56.3)                           
  **Venous invasion**      Negative    31 (36.1)       11 (29.0)              20 (41.7)    0.22
                           Positive    55 (64.0)       27 (71.1)              28 (58.3)     

SD, standard deviation.

Correlation between CD133 and other markers
-------------------------------------------

Table  [2](#T2){ref-type="table"} summarizes the correlation between expression of CD133 and expression of other molecular markers examined. CD133 and p27 expression were positively correlated (*P* = 0.0013), and CD133 and p16 expression tended to be positively correlated (*P* = 0.057) but did not reach statistical significance. No significant correlations were detected between expression of CD133 and expression of any other marker.

###### 

Correlation between expression of CD133 and expression of other molecular markers

                         **Total (%)**   **CD133 expression**               ***P***
  ----------- ---------- --------------- ---------------------- ----------- ---------
  **p53**     Negative   29 (33.7)       13 (34.2)              16 (33.3)   0.93
              Positive   57 (66.3)       25 (65.8)              32 (66.7)   
  **p16**     Negative   69 (80.2)       27 (71.1)              42 (87.5)   0.057
              Positive   17 (19.8)       11 (29.0)              6 (12.5)    
  **p27**     Negative   37 (43.0)       9 (23.7)               28 (58.3)   0.0013
              Positive   49 (57.0)       29 (76.3)              20 (41.7)   
  **MDM2**    Negative   66 (76.7)       31 (81.6)              35 (72.9)   0.35
              Positive   20 (23.3)       7 (18.4)               13 (27.1)   
  **Ki-67**   \<30       43 (50.0)       17 (44.7)              26 (54.2)   0.39
              ≥30        43 (50.0)       21 (55.3)              22 (45.8)   
  **EGFR**    Negative   46 (53.5)       23 (60.5)              23 (47.9)   0.24
              Positive   40 (46.5)       15 (39.5)              25 (52.1)    

Correlations for other molecular markers
----------------------------------------

In terms of correlations between the other molecular markers and clinicopathological findings, p16 expression was correlated with smoking history (*P* = 0.018), pathological lymph node status (*P* = 0.033), and lymphatic invasion (*P* = 0.018) (Additional file [1](#S1){ref-type="supplementary-material"}). With regard to correlations among other molecular markers, p53 expression was positively correlated positively with Ki-67 expression (*P* = 0.0030) (Additional file [2](#S2){ref-type="supplementary-material"}).

Survival analysis
-----------------

The 3- and 5-year survival rates of all patients examined were 65.0% and 61.5%, respectively. Results of univariate analysis of postoperative overall survival (OS) and disease-free survival (DFS) are summarized in Table  [3](#T3){ref-type="table"}. Overall survival was significantly correlated with pT, pN, pStage, and CD133 status, and was significantly longer in CD133-positive patients than in CD133-negative patients (*P* = 0.049) (Figure  [2](#F2){ref-type="fig"}). No significant correlation between OS and the other markers was observed (Figure  [3](#F3){ref-type="fig"}). Multivariate analysis demonstrated that pStage was a significant prognostic factor for OS and that pStage and tumor location were significant prognostic factors for DFS. Correlation between CD133 expression and patient survival did not reach statistical significance by multivariate analysis (Table  [4](#T4){ref-type="table"}).

![**Kaplan-Meier curves of patients with esophageal squamous cell carcinoma according to CD133 expression.** Overall survival was significantly longer in CD133-positive patients than in CD133-negative patients (*P* = 0.049). There was no significant correlation between disease-free survival and CD133 status (*P* = 0.059).](1477-7819-11-51-2){#F2}

![**Kaplan-Meier curves of patients with esophageal squamous cell carcinoma according to expression of the other markers.** No significant correlation between overall survival and the other markers was observed.](1477-7819-11-51-3){#F3}

###### 

Univariate survival analysis of clinicopathological findings and expression of molecular markers

                       **Variables**       **Number**   **Overall survival**   **Disease-free survival**         
  -------------------- ------------------ ------------ ---------------------- --------------------------- ------ --------
  Age (years)          ≤60                     29               72.4                     0.11              62.1    0.21
                       \>60                    57               55.9                     52.5                    
  Sex                  Male                    73               58.7                     0.13              51.9   0.080
                       Female                  13               76.9                     76.9                    
  Location             Cervix/upper            10               50.0                     0.12              40.0   0.067
                       Middle/lower            76               63.0                     57.8                    
  Histological type    Well or moderate        73               61.5                     0.64              57.4    0.36
                       Poor                    13               61.5                     46.2                    
  pT                   pT1/pT2                 37               78.1                    0.0012             70.0   0.0033
                       pT3/pT4                 49               49.0                     44.9                    
  pN                   pN0                     36               80.6                    0.0051             75.0   0.0078
                       pN1-3                   50               47.7                     41.7                    
  pStage               pStageI/II              48               79.0                    0.0002             72.8   0.0002
                       pStageIII/VI            38               39.5                     34.2                    
  Lymphatic invasion   Negative                34               70.2                     0.086             58.4    0.29
                       Positive                52               55.8                     53.9                    
  Venous invasion      Negative                31               64.5                     0.47              54.8    0.63
                       Positive                55               59.8                     56.2                    
  p53                  Negative                29               62.1                     0.30              55.2    0.55
                       Positive                57               61.3                     56.1                    
  p16                  Negative                69               58.0                     0.19              53.6    0.14
                       Positive                17               76.0                     63.7                    
  p27                  Negative                37               56.8                     0.30              54.0    0.49
                       Positive                49               65.0                     56.9                    
  MDM2                 Negative                66               63.6                     0.31              59.1    0.61
                       Positive                20               53.3                     59.2                    
  Ki-67                \<30                    43               69.8                     0.24              62.8    0.27
                       ≥30                     43               53.2                     48.6                    
  EGFR                 Negative                46               69.6                     0.22              63.0    0.16
                       Positive                40               52.0                     47.1                    
  CD133                Negative                48               54.2                     0.049             47.9   0.059
                       Positive                38               70.8                                       65.5      

###### 

Multivariate survival analysis of clinicopathological findings and expression of molecular markers

                                **Variables**     **Hazard ratio**   **95% confidence interval**   ***P***
  ----------------------------- ---------------- ------------------ ----------------------------- ---------
  **Overall survival**          pStageIII/IV            2.64                  1.42-5.03            0.0020
  Lymphatic invasion positive   1.48                 0.79-2.89                  0.23              
  CD133 negative                1.74                 0.94-3.35                  0.078             
  **Disease-free survival**     Male                    2.09                  0.84-6.99             0.12
                                Cervix/upper            2.51                  1.07-5.21             0.035
                                pStageIII/IV            2.93                  1.62-5.42            0.0004
                                CD133 negative          1.73                  0.96-3.24             0.071

Discussion
==========

CD133 was originally identified as a transmembrane glycoprotein in normal hematopoietic stem and progenitor cells \[[@B31]\] that participated in proliferation, self-renewal, and multilineage differentiation \[[@B32]\]. Furthermore, CD133 was recently used to identify putative cancer stem cells of several tumors \[[@B33]\]. According to several studies, CD133 was associated with tumor differentiation in several organs \[[@B16],[@B34]-[@B36]\]. For example, Jiang *et al*. \[[@B36]\] reported that CD133 expression was increased in diffuse-type gastric cancers compared with intestinal-type cancers and was increased more so in poorly differentiated than in moderately or well differentiated gastric cancers. In addition, Feng *et al*. \[[@B35]\] reported that CD133 was negatively correlated with the cellular differentiation status of colon cancer cells. Finally, Fan *et al*. \[[@B34]\] reported that CD133 expression was correlated with well differentiated or moderately differentiated cholangiocarcinomas and that subcellular CD133 localization was correlated with the tumor differentiation status. In terms of ESCC, Hang *et al*. reported that CD133 expression was increased in well differentiated and moderately differentiated ESCCs compared with poorly differentiated ESCCs \[[@B30]\]. However, in our study, no correlation was detected between CD133 expression and tumor differentiation of carcinoma cells. We think that this was because there is a difference among pathologists or facilities regarding the histological evaluation of tumor differentiation status, and in addition, our study was small. On the other hand, CD133 expression correlated with p27 expression (*P* = 0.0013) and tended to correlate with the status of p16 immunoreactivity (*P* = 0.057). The relationship between CD133 and cell cycle regulators has remained unclear in esophageal cancer. There may be a correlation between CD133 and cell cycle pathways associated with the INK4 family or the CIP/KIP family of cyclin-dependent kinase inhibitors \[[@B37]\], but this possibility requires further investigation.

To the best of our knowledge, there are few reports that have investigated the effect of CD133 expression on survival of ESCC patients. Nakajima *et al*. \[[@B38]\] reported that CD133 expression in resected ESCC specimens following neoadjuvant chemoradiotherapy tended to be correlated with poor prognosis, but multivariate analysis did not produce a significant correlation. In contrast, CD133 expression was significantly correlated with poor response to neoadjuvant chemoradiotherapy. Hang *et al*. \[[@B30]\] reported that CD133 expression in resected ESCC specimens without preoperative treatment was not significantly correlated with prognosis. Our study revealed that OS was significantly longer in CD133-positive patients than in CD133-negative patients, as determined by log-rank test. One reason for this was that the tumors were significantly more advanced (according to their pStage classification) in CD133-negative patients than in CD133-positive patients. Although correlation between CD133 expression and patient survival did not reach statistical significance, as determined by multivariate analysis, CD133 immunoreactivity may have the potential to be a good predictor of prognosis in ESCC patients. With regard to other tumors, CD133 expression in non-small cell lung cancers \[[@B39],[@B40]\], hepatocellular carcinomas \[[@B18]\], and pancreatic cancers \[[@B41]\] was not correlated with patient survival. Moreover, CD133-negative expression in cholangiocarcinomas was correlated with poor prognosis \[[@B34]\], which is similar to that revealed in our study. Further studies are needed to clarify this issue.

Conclusions
===========

In conclusion, this study demonstrated that CD133 immunoreactivity may have the potential to be a good predictor of prognosis in ESCC patients, and that CD133 may play a role in the regulation of tumor cell cycle through p27 and p16 in ESCC. At present, whether CD133 expression is a valid prognostic marker for ESCC remains controversial. To elucidate this relationship, further investigations are required, including verification of an evaluation method for CD133 immunoreactivity in ESCC.
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###### Additional file 1

**Correlation between clinicopathological findings and p16 status.** p16 expression was correlated with smoking history (*P* = 0.018), advanced pN (*P* = 0.033), and lymphatic invasion (*P* = 0.018).
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###### Additional file 2

**Correlation between p53 status and Ki-67 status, MDM2 status.** p53 expression was positively correlated with Ki-67 expression (*P* = 0.0030).
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